微創醫療(00853.HK):心脈醫療科技預計前三季度淨利同比增長約20.36%
格隆匯10月23日丨微創醫療(00853.HK)公佈,預料上海微創心脈醫療科技(集團)股份有限公司("心脈醫療科技")於截至2022年9月30日止九個月錄得利潤增長。
公司持有心脈醫療科技46.34%的股份,其業績與公司財務報表綜合入賬。心脈醫療科技的股份在上海證券交易所科創板上市。
於截至2022年9月30日止九個月,預計歸屬於心脈醫療科技所有者的淨利潤為人民幣30,088.35萬元,與上年同期相比增加約20.36%;歸屬於心脈醫療科技所有者的扣除非經常性損益的淨利潤為人民幣27,557.69萬元,與上年同期相比增加約18.24%。於2022年第三季度(七月至九月),預計實現歸屬於心脈醫療科技所有者的淨利潤為人民幣8,584.7萬元,同比增加約31.51%;實現歸屬於心脈醫療科技所有者的扣除非經常性損益的淨利潤為人民幣7,092.21萬元,同比增加約32.96%。
利潤增長主要原因系2022年前九個月,創新性產品Castor®分支型主動脈覆膜支架及輸送系統、Minos®腹主動脈覆膜支架及輸送系統、Reewarm®PTX藥物球囊擴張導管等產品均實現快速增長,進一步提高了心脈醫療科技在主動脈及外周血管介入市場的競爭力,導致銷售收入較去年同期實現較快增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.